Next Article in Journal
Systemic Targeted Therapy for her2-Positive Early Female Breast Cancer: A Systematic Review of the Evidence for the 2014 Cancer Care Ontario Systemic Therapy Guideline
Previous Article in Journal
Isolated Brain Metastases as First Site of Recurrence in Prostate Cancer: Case Report and Review of the Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 22
Issue 6
10.3747/co.22.2700
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Does CDKN2A Loss Predict Palbociclib Benefit?

by
J. Gao
1,
R.P. Adams
2 and
S.M. Swain
2,*
1
National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
2
Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2015, 22(6), 498-501; https://doi.org/10.3747/co.22.2700
Submission received: 4 September 2015 / Revised: 6 October 2015 / Accepted: 8 November 2015 / Published: 1 December 2015

Abstract

Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, her2-negative breast cancer. Patients with loss of CDKN2A (p16), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor–positive, her2-negative breast cancer with CDKN2A loss who experienced a clinical response to palbociclib.
Keywords: medical oncology; breast cancer medical oncology; breast cancer

Share and Cite

MDPI and ACS Style

Gao, J.; Adams, R.P.; Swain, S.M. Does CDKN2A Loss Predict Palbociclib Benefit? Curr. Oncol. 2015, 22, 498-501. https://doi.org/10.3747/co.22.2700

AMA Style

Gao J, Adams RP, Swain SM. Does CDKN2A Loss Predict Palbociclib Benefit? Current Oncology. 2015; 22(6):498-501. https://doi.org/10.3747/co.22.2700

Chicago/Turabian Style

Gao, J., R.P. Adams, and S.M. Swain. 2015. "Does CDKN2A Loss Predict Palbociclib Benefit?" Current Oncology 22, no. 6: 498-501. https://doi.org/10.3747/co.22.2700

APA Style

Gao, J., Adams, R. P., & Swain, S. M. (2015). Does CDKN2A Loss Predict Palbociclib Benefit? Current Oncology, 22(6), 498-501. https://doi.org/10.3747/co.22.2700

Article Metrics

Back to TopTop